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Abstract
It was recently reported that when mosquitoes infected with P. berghei sporozoites feed on mice, they deposit
approximately 100–300 sporozoites in the dermis. When we inoculate P. yoelii (Py) sporozoites intravenously (IV) into BALB/c
mice, the 50% infectious dose (ID50) is often less than 3 sporozoites, indicating that essentially all Py sporozoites in salivary
glands are infectious. Thus, it should only take the bite of one infected mosquito to infect 100% of mice. In human subjects,
it takes the bite of at least 5 P. falciparum-infected mosquitoes to achieve 100% blood stage infection. Exposure to 1–2
infected mosquitoes only leads to blood stage infection in approximately 50% of subjects. If mosquitoes carrying Py
sporozoites inoculate 100–300 sporozoites per bite, and 1 to 2 mosquito bites achieve 50% blood stage infection rates, then
this would suggest that the majority of sporozoites inoculated by mosquitoes into the dermis are not responsible for a
productive infection, or that a significant number of sporozoite-infected mosquitoes do not inoculate any sporozoites. The
objective of this study was to determine if this is the case. We therefore studied the infectivity to mice of the bites of 1, 2, 4,
or 5–8 Py-infected mosquitoes. The bite of one Py sporozoite-infected mosquito caused blood stage infection in 41.4% (12/
29) of mice, two bites infected 66.7% (22/33), four bites infected 75% (18/24), and five to eight bites infected 100% (21/21).
These findings demonstrate that inoculation of sporozoites by mosquito bite is much less efficient than IV inoculation of Py
sporozoites by needle and syringe. Such data may have implications for determining the best route and dose of
administration to humans of our attenuated P. falciparum sporozoite vaccine, the scientific basis of which is immunity by
bites from irradiated infected mosquitoes, and suggest that the challenge is to develop a method of administration that
approximates IV inoculation, not one that mimics mosquito bite.
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Introduction
We are currently developing a metabolically active, non-
replicating (attenuated) Plasmodium falciparum sporozoite malaria
vaccine (PfSPZ Vaccine) [1]. The immunogen in the PfSPZ
Vaccine is P. falciparum sporozoites isolated from salivary glands of
irradiated Anopheles mosquitoes. Fifteen of sixteen (94%) human
volunteers exposed to the bites of greater than 950 irradiated
Anopheles species mosquitoes with P. falciparum sporozoites in their
salivary glands were protected against challenge by the bites of five
mosquitoes infected with fully virulent P. falciparum sporozoites [2].
Only four of ten volunteers exposed to fewer than 950 bites were
protected. Thus, there is a dose response and the numbers of
sporozoites inoculated is critical for achieving optimal protection.
The development of the PfSPZ Vaccine requires optimizing the
dose and method of administration of the P. falciparum sporozoites.
In mice, 3 doses of 750 radiation-attenuated P. yoelii sporozoites
(total number of sporozoites=2250) administered intravenously
(IV) leads to between 90% and 100% protection against virulent
challenge [3]. This level of protection can be achieved by
intradermal or subcutaneous inoculation of the sporozoites, but
more sporozoites are required. Because the development of the
PfSPZ Vaccine is based on the results of studies in which humans
were immunized by the bite of infected mosquitoes, we reasoned
that determining the efficiency of transmission of P. yoelii to mice
by sporozoite-infected Anopheles sp. mosquitoes would serve as a
model to help us make predictions on the optimal dose and route
of PfSPZ Vaccine in humans. Therefore, in multiple experiments,
we assessed the capacity of one to eight P. yoelii sporozoite-infected
A. stephensi to infect mice and determined the 50% infectious dose
(ID50)o fP. yoelii sporozoites from these same mosquitoes, when
inoculated IV. The results indicate that mosquitoes are far less
efficient at transmitting malaria than is an IV injection, and
suggest that optimizing the protective efficacy of the PfSPZ
Vaccine will require developing a vaccine administration system
that is as efficient as IV inoculation.
Materials and Methods
Mosquitoes
Anopheles stephensi derived from two colonies maintained at
Sanaria, and designated as Anopheles stephensi (NIJ.SAN01) and
Anopheles stephensi (SXK.SAN02) were used.
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Non lethal Plasmodium yoelii 17XNL (clone 1.1) [4] was
maintained by alternating passage of the parasites in A. stephensi
mosquitoes and CD-1 mice (Harlan Laboratories, IN).
Infection of Mosquitoes
The IACUC committee of the University of Maryland
Biotechnology Institute (UMBI), Rockville, Maryland, approved
all animal experiments described in the study. UMBI’s animal
facility was used to house the mice and all experiments were
conducted at UMBI. Five day-old heat-selected female A. stephensi
mosquitoes were fed on 4–6 week-old HSD:ICR(CD-1H) mice
(Harlan Bioproducts, Indianapolis, IN) infected with P. yoelii (clone
1.1) [4], and maintained for 14–17 days to allow for sporozoite
development.
Exposure of Naı ¨ve BALB/c Mice to Bites of P. yoelii
Infected Mosquitoes
Six-8 week old BALB/c mice (Harlan Bioproducts, Indianapo-
lis, IN, and NCI, Frederick, MD) were anesthetized by
intraperitoneal injections of sodium pentobarbital (Sigma-Aldrich,
St. Louis, MO). The ventral surface (primarily abdomen) of each
mouse was placed on a screened cardboard container harboring
sporozoite-infected female A. stephensi mosquitoes, which were
allowed to feed for 20 minutes. Mosquitoes that fed on mice were
checked for the presence of a blood meal in their abdomen and
sporozoites in their salivary glands. In some experiments, the
mosquitoes that did not have a blood meal in their abdomens and/
or sporozoites in their salivary glands were replaced by another
mosquito until the pre-designated number of infected mosquitoes
had fed.
Estimation of Numbers of Sporozoites per Mosquito
Individual salivary gland squashes. Mosquitoes that had
taken a blood meal were dissected individually. The salivary
glands were removed and squashed under a cover slip, and were
analyzed under a microscope at 2006 magnification. The
presence of sporozoites was determined by counting the number
of sporozoites (PySPZ) per 5–10 fields and scored according to the
following method: 0=no PySPZ seen in the glands; 1+=1–
10 PySPZ/field; 2+=11–100 PySPZ/field; 3+=.100 PySPZ/
field. It was estimated that, per mosquito, there were approx-
imately 250 fields containing salivary gland material. Thus, a
mosquito with a 1+ score would have an estimated minimum of
250 sporozoites/mosquito and a maximum of 2500 sporozoites
per mosquito. It should be noted that this scoring system differs
from the traditional system [5], in which 1+=1–10 PySPZ/
mosquito; 2+=11–100 PySPZ/mosquito; 3+=101–1000 PySPZ/
mosquito, and 4+=.1000 PySPZ/mosquito.
Pooled salivary gland preparations. For experiments in
which the number of sporozoites per mosquito was determined,
salivary glands from 10–350 mosquitoes from the same
experiment were pooled and sporozoites were counted in a
hemocytometer. To determine the mean number of sporozoites
per mosquito, the total number of sporozoites was divided by the
number of mosquitoes dissected.
Assessment of Blood Stage Parasitemia
Infections in mice were determined by examining Giemsa-
stained thin blood smears (at 10006 magnification) for the
presence of blood stage parasites on days 7 and 14 after exposure
to mosquito bites.
Determination of ID50 (50% Infectious Dose)
P. yoelii sporozoites were harvested from hand-dissected salivary
glands of A. stephensi and diluted in E-199 medium without L-
glutamine (Quality Biological, Inc. Gaithersburg, MD) with 1%
Human Serum Albumin (HSA). Four groups of five 6–8 week old
female BALB/c mice were inoculated by the intravenous (IV)
route with 24 PySPZ/mouse, 12 PySPZ/mouse, 6 PySPZ/
mouse, and 3 PySPZ/mouse respectively. The infections in the
mice were determined 14 days later and the ID50 was calculated as
follows: the % infected mice per group (X/56100) was plotted
against the number of sporozoites inoculated. A non-linear
exponential association curve (CurveExpert 1.3) was used to
calculate the number of sporozoites required to generate a 50%
infection rate (ID50). The curve fit included a zero data point (an
administration of 0 sporozoites would lead to 0% infection).
Results
Efficiency of Transmission of Infection by Mosquito Bite
To determine the number of bites required for the establish-
ment of asexual erythrocytic stage infection in mice, one to eight A.
stephensi mosquitoes with P. yoelii sporozoites in their salivary glands
were allowed to feed on the ventral surface (primarily abdomen) of
BALB/c mice for twenty minutes. Confirmation that the
mosquitoes had taken a blood meal was made by identifying
blood in the abdomen of individual mosquitoes dissected
immediately after feeding. Confirmation of the presence of
sporozoites in the mosquitoes was established by microscopic
analysis of salivary gland preparations from individual mosquitoes.
In these experiments, only mice that were exposed to blood-fed
infected mosquitoes were considered in the analysis. On days 7
and 14 following feeding, blood smears were assessed for asexual
erythrocytic-stage parasitemia. The data from 5 separate exper-
iments are shown in Table 1. The combined data from the first 4
experiments indicated that 43% (10/23) of mice that received 1
bite developed parasitemia, 63% (17/27) that received 2 bites
developed parasitemia, and 64% (9/14) that received 4 bites
developed parasitemia. 100% (15/15) of mice that received
between 5 and 8 bites developed blood stage parasitemia.
Numbers of Sporozoites per Mosquito
Microscopic analyses of salivary gland squashes from each
mosquito that had fed on a mouse were performed, and the results
demonstrated that the mosquitoes had substantial numbers of
sporozoites. The results of the salivary gland scores from the
salivary gland squashes from all experiments in which a mouse was
exposed to a single mosquito are reported in Table 2.
Recognizing the sensitivity limitations of this semi-quantitative
method, there was no indication that the sporozoite load was
different in mosquitoes that transmitted or did not transmit an
infection. To further refine our understanding of the numbers of
sporozoites per mosquito and to eliminate the possibility that low
numbers of sporozoites in the salivary glands of mosquitoes were a
contributing factor to the low transmission rate, the mean number
of sporozoites per mosquito in each container was determined.
Mosquitoes raised in the same containers as the mosquitoes used
to bite mice were assessed. Salivary glands were dissected from
these mosquitoes and pooled sporozoites were counted. The mean
numbers of sporozoites per mosquito from experiments 1 through
5 are shown in Table 3. The mean number of sporozoites per
mosquito for experiments 1 through 4 was 23,198 and the range
from container to container was 16,500 to 27,875. Therefore,
insufficient numbers of sporozoites/mosquito was not the reason
for the low infection rate. Furthermore, sporozoite burden in the
Malaria Transmission
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transmission to occur.
Infection Rates with Mosquitoes Derived from a Second
Colony
It was possible that the inefficient transmission observed was due
to factors in the mosquitoes that were specific to our mosquito
colony. To address this, a separate source of A. stephensi was
identified, A. stephensi eggs were obtained, and mosquitoes were
reared in our insectary. The mosquitoes were infected by feeding on
parasitemic mice, and the experiment was conducted as above.
Infection rates in mice exposed to 2 (5/6) or 4 bites (9/10) were
higher than previously observed (Table 1, Experiment 5), but it
stillrequired atleast5 bitesto achieve infectionof100% ofthe mice,
and only 33% (2/6) of mice became parasitemic following a single
mosquito bite. Mosquitoes in this experiment had an average of
83,875 sporozoites per salivary gland (Table 3). Therefore, despite
the presence of large numbers of sporozoites in the salivary glands,
transmission by a single bite by these mosquitoes reared from eggs
from a different colony was also not efficient.
Difference in Infectivity of Sporozoites Inoculated by
Mosquito Bite or Intravenous Injection
Despite our multiple publications [3,6,7] over the past two
decades demonstrating the high level of infectivity of P. yoelii
sporozoites when administered by intravenous (IV) injection, it
was possible that the P. yoelii sporozoites in the mosquitoes used in
our experiments (Table 1) were intrinsically non-infective.
Therefore, in the last experiment, we dissected salivary glands
from mosquitoes raised in the same container as the mosquitoes
used to feed on mice (Table 1, Experiment 5), injected the
sporozoites in the tail veins of mice, assessed the mice for
parasitemia on days 7 and 14, and calculated the 50% infectious
dose (ID50) of the P. yoelii sporozoites (Table 4). When 3
sporozoites were injected IV, 80% of mice developed asexual
erythrocytic stage parasitemia. The ID50 was extremely low, and
estimated to be 1.09. Therefore, the low rate of transmission of
infection from mosquito bites was not due to poor infectivity of the
sporozoites.
Discussion
The data reported herein indicate that the majority of P. yoelii
sporozoites inoculated into the dermis of BALB/c mice by A.
stephensi mosquitoes do not lead to a productive infection; they do
not result in asexual erythrocytic stage infections that cause the
disease known as malaria. An alternative and complimentary
explanation is that a significant percentage of P. yoelii sporozoite-
infected mosquitoes that feed do not inoculate sporozoites.
Exposure to one, two or four PySPZ-infected mosquitoes led to
asexual erythrocytic stage infection in 41.4% (12/29), 66.7% (22/
Table 1. Infection rates after exposure to the bite of one to eight P. yoelii-infected mosquitoes.
experiment # A. stephensi strain infected/challenged (% infected)
1 bite 2 bites 4 bites 5–8 bites
1 NIJ.SAN01 2/9 4/10 N/A N/A
2 NIJ.SAN01 1/4 7/9 5/7 10/10
3 NIJ.SAN01 6/9 4/6 N/A N/A
4 NIJ.SAN01 1/1 2/2 4/7 5/5
total (1–4) 10/23 (43%) 17/27 (63%) 9/14 (64%) 15/15 (100%)
5 SXK.SAN02 2/6 (33%) 5/6 (83%) 9/10 (90%) 6/6 (100%)
total (1–5) 12/29 (41.4%) 22/33 (66.7%) 18/24 (75%) 21/21 (100%)
BALB/c mice were exposed to one, two, four, or five to eight bites by A. stephensi mosquitoes infected with P. yoelii sporozoites. 7 and 14 days following bites, mice were
assessed for parasitemia by blood smear. Data from individual mice from five separate experiments (experiments 1–5) are shown. A single strain of A. stephensi
(NIJ.SAN01) was used in experiments 1–4 and a second strain (SXK.SAN02) in experiment 5.
doi:10.1371/journal.pone.0008947.t001
Table 2. Salivary gland scores of individual mosquitoes in Experiments 1–5.
experiment #
infected/challenged from one
mosquito bite salivary gland scores
mice that developed parasitemia mice that did not develop parasitemia
1 2 / 9 2 ,2 2 ,3 ,3 ,2 ,2 ,3 ,2
2 1/4 3 2, 1, 3
3 6/9 3, 3, 3, 3, 3, 3 3, 3, 1
4 1/1 2
5 2 / 6 3 ,3 3 ,1 ,3 ,3
geometric mean (range) 2.71 (2–3) 2.21 (1–3)
After feeding, the mosquitoes were dissected to demonstrate that they had taken a blood meal and establish the salivary gland score (1+ to 3+, see Methods). Nine of
the 17 mosquitoes that fed on mice that did not develop parasitemia (negatives) had the highest salivary gland score of 3+. The geometric mean salivary gland scores of
the mosquitoes were not significantly different between the two groups (p=0.2856, Wilcoxon Two Sample Test).
doi:10.1371/journal.pone.0008947.t002
Malaria Transmission
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eight PySPZ-infected mosquitoes infected 100% (21/21) (Table 1).
Despite the poor infectivity after one mosquito bite (41.4%), the
data (Table 4) confirm the established fact [3,6,7] that almost all
P. yoelii sporozoites in the salivary glands are infectious. When
administered IV, the 50% infectious dose (ID50) is extremely low,
and in the case of the experiment reported in Table 4, the ID50
was only 1.09 sporozoites. This is an important finding, because
without such data it could be argued that only the sporozoites that
are most infectious make it to the mosquito proboscis for
inoculation by mosquitoes.
It was previously shown that there was a requirement for
exposure to the bites of at least five P. berghei sporozoite-infected
mosquitoes to achieve 100% infection of CD-1 mice, and fewer
that three bites resulted in no infections [8]. No parallel
intravenous (IV) inoculation of sporozoites was performed.
However, the authors reported that in other published experi-
ments with P. berghei sporozoites the ID50 of sporozoites inoculated
intravenously to CD-1 mice was extremely high (1,700 to 11,500)
indicating that the sporozoite infectivity was extremely poor
[9,10]. It should also be noted that differences in infectivity are
also dependent on parasite and mouse strain, as P. berghei
sporozoites are more infectious in H2
b haplotype mice such as
B/6 and B/10 strains, and P. yoelii are more infectious in BALB/c
mice. Because of the poor infectivity of P. berghei sporozoites, we
and others [11] moved from the P. berghei to the P. yoelii rodent
model system, as the high infectivity of P. yoelii sporozoites in mice
is thought to closely resemble the infectivity of P. falciparum and P.
vivax in humans and P. knowlesi in rhesus monkeys.
Although parallel mosquito bite and IV administration of P.
falciparum sporozoites has not been done in recent human studies, the
mosquito bite findings are consistent with published work on
transmission of P. falciparum to volunteers by the bite of A. stephensi.
In 1986 it was demonstrated that exposure of volunteers to five A.
stephensi mosquitoes infected with P. falciparum sporozoites in their
salivary glands resulted in asexual erythrocytic stage infection in all
volunteers [5]. This has been repeated in more than 500
volunteers in the published literature and summarized [12,13].
Exposure to the bites of 5 mosquitoes infected with P. falciparum
essentially always leads to parasitemia. To determine if five
mosquitoes were too many, and might overwhelm subunit vaccine-
induced protective immunity, Rickman and colleagues [14]
studied the capacity of 1 or 2 infected mosquitoes to transmit P.
falciparum to volunteers. When the subjects were exposed to the
bites of 1–2 P. falciparum (3D7 clone of the NF54 strain) infected A.
stephensi mosquitoes, only 5 of 10 (50%) became infected with
blood stage parasites. Verhage and colleagues [15] confirmed
these findings. They showed that when human volunteers were
exposed to the bites of 1–2 P. falciparum (NF54 strain) infected A.
stephensi mosquitoes, 5 of 10 (50%) became infected and when
exposed to the bites of 4–7 infected mosquitoes, 13/13 (100%)
developed asexual erythrocytic stage infection. Thus, our findings
in mice are analogous to what has been found in humans.
Based on work with the human malaria parasite, P. falciparum,i n
A. freeborni, A. gambiae, and A. stephensi mosquitoes, most
malariologists have thought that mosquitoes inoculate about 5–
25 sporozoites when they feed [16,17]. Recent elegant work in
mice using rodent malaria (P. berghei) sporozoites expressing a
fluorescent protein has demonstrated that A. stephensi inoculate at
least 100 and perhaps 300 P. berghei sporozoites into the dermis of
mice [18]. Those findings are consistent with studies using
transgenic P. berghei expressing b-galactosidase, and with polymer-
ase chain reaction studies with P. yoelii [19,20]. If our P. yoelii
sporozoite-infected mosquitoes behave like the P. berghei and P.
yoelii-sporozoite-infected mosquitoes reported on in these studies,
and inoculate 100 sporozoites into the dermis, then our data
demonstrate that in at least half the cases, none of the hundred or
so sporozoites inoculated by a single mosquito invades hepato-
cytes, develops to a mature liver stage schizonts, and produces
merozoites that infect erythrocytes. One explanation for this is that
the sporozoites never migrate from the skin to the liver. It has been
shown that sporozoites are deposited into the dermal tissue by
Anopheles during probing, and slowly migrate out of the inoculation
site [21,22]. Many of these sporozoites are likely trapped in the
local draining lymph nodes or encounter host defense mechanisms
in the skin [23,24,25]. Another explanation may be that some of
the failures to achieve infection were due to lack of inoculation of
sporozoites rather than lack of successful migration to and
development in the liver. It has been shown that approximately
22% of P. yoelii sporozoite-infected mosquitoes do not inoculate
any sporozoites when feeding [20]. The density of salivary gland
infection apparently does not impact either of these potential
mechanisms, since after exposure to a single infected mosquito
there was no difference in the estimated numbers of sporozoites in
the glands of mosquitoes that did and did not give rise to a patent
infection (Table 2).
Our goal is to develop a highly protective attenuated P.
falciparum sporozoite vaccine. Currently the optimal dose and route
of administration of P. falciparum sporozoites are not known. It
takes exposure to greater than 950 bites from irradiated P.









mean # of Py
sporozoites/
mosquito
1 350 9,298,450 26,567
2 20 557,500 27,875
3 10 218,500 21,850
4 132 2,178,000 16,500
5 15 1,258,125 83,875
The numbers of sporozoites was determined in salivary glands of mosquitoes
from the same container as the mosquitoes used in the experiments. Salivary
glands from the indicated number of mosquitoes were pooled, sporozoites
were isolated from the salivary glands, the total numbers of sporozoites were
determined, and the mean numbers of sporozoites/mosquito were calculated.
doi:10.1371/journal.pone.0008947.t003
Table 4. Infectivity of PySPZ inoculated IV.











A sample of 15 mosquitoes was randomly taken from the same container in
which the mosquitoes used to bite mice in experiment #5 were taken. Salivary
glands were dissected from the 15 mosquitoes and sporozoites isolated. The
indicated numbers (first column) were injected IV into mice. 7 days and 14 days
later, the presence of parasitemia was determined by microscopic evaluation of
thin blood smears. The ID50 was calculated, and determined to be 1.09 PySPZ.
doi:10.1371/journal.pone.0008947.t004
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protective immunity in humans [2]. Based on the analyses of
efficiency of sporozoite transmission, one can estimate the dose of
sporozoite vaccine required for protection. If one assumes that
each bite results in sporozoite inoculation, and 5, 25, 100, or 300
sporozoites are in each inoculant, then it can be estimated that an
immunizing regimen of 5,000, 25,000, 100,000 or 300,000
sporozoites would be required to achieve high-level protection in
humans, if the sporozoites inoculated by needle are similar in
potency to sporozoites delivered through intradermal inoculation
by mosquitoes. It takes an immunizing regimen of only 3 doses of
750 P. yoelii sporozoites (2,250 total) administered IV to
consistently achieve 90% to 100% protection in mice [3]. In
contrast it takes administration of at least 1,500 attenuated P. yoelii
sporozoites given in 4 doses (6,000 total) to mice by the ID or SC
routes to achieve comparable protection (unpublished). Further-
more, at least twice as many purified, cryopreserved attenuated Py
sporozoites are required for protection by ID or SC routes
compared to the IV route [26]. In the long run, our goal is to
achieve 90% to 100% protection of humans by administration of
the fewest numbers of doses of an attenuated PfSPZ vaccine
containing the lowest numbers of sporozoites. Murine and human
data suggest that a significant proportion of sporozoites inoculated
by mosquitoes do not lead to productive infections. Thus, as we
move toward optimizing the efficiency of immunization of humans
with the PfSPZ Vaccine, we are using immunity achieved by
intravenous inoculation of sporozoites as the standard we would
like to achieve through non-intravenous parenteral adminstration.
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